Core Points - The stock price of HeFu China (603122) increased by 2.07% to 6.89 CNY as of July 4, 2025, with a market capitalization of 2.743 billion CNY [1] - The company completed the cancellation of its initial public offering (IPO) fundraising account, with a total fundraising amount of 416.96 million CNY and a net amount of 359.69 million CNY after expenses [1][2] - HeFu China announced a cash dividend of 0.13 CNY per share for the 2024 annual equity distribution, totaling 51.75 million CNY [3] Company Announcements - HeFu China has completed the cancellation of its IPO fundraising account, with the balance of 58.45 million CNY transferred to the general account [2] - The company signed a tripartite supervision agreement regarding the fundraising account and later terminated it after the account's cancellation [2] - The cash dividend distribution was approved at the annual shareholders' meeting on June 25, 2025, with specific tax implications for different types of shareholders [3]

Core Viewpoint - The company has completed the cancellation of its fundraising special accounts, following the approval of its fundraising management and usage protocols, ensuring compliance with regulatory requirements [1][2][3]. Fundraising Basic Information - The company raised a total of RMB 416,960,308.00 through its initial public offering of 99,513,200 shares at a price of RMB 4.19 per share, with all funds received by February 11, 2022 [1]. Fundraising Management and Storage - The company established a fundraising management system to ensure proper storage and usage of the raised funds, signing a tripartite supervision agreement with relevant banks and its sponsor [2]. - A quadripartite supervision agreement was later signed to allow the company to provide loans to its wholly-owned subsidiary for project implementation [2]. Fundraising Account Cancellation - The company decided to open a new special account for fundraising to improve the yield of the raised funds and subsequently canceled the previous accounts, with the cancellation process completed by March 11, 2025 [3][4]. - The total balance of the canceled fundraising accounts was transferred to the new account, and all relevant agreements were terminated [4].

证券代码：603122 证券简称：合富中国 公告编号：临 2025-029 合富（中国）医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.13元 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/11 | － | 2025/7/14 | 2025/7/14 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 25 日的2024年年度股东会审议通过。 本次利润分配以方案实施前的公司总股本398,052,633股为基数，每股派发现金红利0.13 元（含税），共计 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-030 合富（中国）医疗科技股份有限公司 关于募集资金专户完成销户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司本次注销的募集资金专户信息如下： 二、募集资金存放和管理情况 为规范公司募集资金管理和使用，保护投资者权益，按照《中华人民共和国 公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》和《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等有关法律、法规和规范性文 件的规定，结合公司实际情况，公司已制定了《募集资金管理制度》，对募集资 金实行专户存储制度，对募集资金的存放、使用、项目实施管理、投资项目的变 更及使用情况的监督进行了规定。公司于 2022 年 2 月与保荐机构海通证券股份 有限公司、存放募集资金的上海银行虹桥路支行、兴业银行股份有限公司上海分 1 行营业部、富邦华一银行有限公司上海徐汇支行、招商银行股份有限公司上海分 行营业部分别签署 ...

Group 1 - The first meeting of the third board of directors of Hefei (China) Medical Technology Co., Ltd. was held on June 25, 2025, with all six directors present, and the meeting was conducted legally and effectively [1] - Li Jun was elected as the chairman of the third board of directors, with a term lasting until the end of the current board's term [1][2] - The board approved the election of various specialized committees, with Li Jun serving as the chairman of the Strategy and ESG Committee [2] Group 2 - Wang Qiongzhi was appointed as the general manager, with a term lasting until the end of the current board's term [3] - The board also appointed Zeng Guankai, Wang Fenghua, and Chen Ye as vice general managers, and Wang Qiongzhi as the financial supervisor [3][4] - Zhu Ying was appointed as the board secretary, and Xu Jiayuan was appointed as the securities affairs representative, both with terms until the end of the current board's term [3][4]

Core Viewpoint - The legal opinion letter issued by Beijing Global Law Firm Shanghai Branch confirms that the 2024 Annual General Meeting of Shareholders of HeFu (China) Medical Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting procedures and voting results [1][3][22]. Group 1: Meeting Procedures - The annual general meeting was held on June 25, 2025, with the notice published on June 5, 2025, meeting the requirement of a 20-day advance notice [3][5]. - The meeting was conducted at the specified location, and both on-site and online voting options were provided to shareholders [5][6]. Group 2: Qualifications of Participants - The second board of directors of HeFu China convened a meeting on June 4, 2025, to propose the annual general meeting, confirming the board as the convener [5][6]. - A total of 3 shareholders and their proxies attended the meeting, representing 792,224 shares, which is 0.1990% of the total voting shares [5][6]. Group 3: Proposals and Voting Procedures - No additional proposals were made beyond those listed in the meeting notice, and all proposals were voted on as stated [6][22]. - The voting process combined both on-site and online methods, with shareholders required to choose one voting method [7][22]. Group 4: Voting Results - The voting results for various proposals showed overwhelming support, with the majority receiving over 99% approval [8][9][10][11][12][13][14][15][16][17][18][19][20][21]. - Specific proposals included the annual board work report, independent director's report, and financial statements, all of which received high approval rates [8][9][10][11][12][19].

Meeting Overview - The annual general meeting of the company was held on June 25, 2025, at the Guangqi Building, Shanghai [1] - The meeting was conducted in compliance with the Company Law of the People's Republic of China and the company's articles of association [1] Attendance and Voting - The meeting was attended by shareholders representing a significant majority of the voting rights, with various voting methods including on-site and online participation [1] - The voting results showed a high level of agreement among shareholders, with most resolutions passing with over 99% approval [1][2][3] Resolutions Passed - Multiple resolutions were approved, including those related to the election of directors and the authorization for changes in business registration [1][2][3] - Specific voting results included: - 224,829,664 votes in favor (99.7408%) for one resolution [1] - 224,805,364 votes in favor (99.7300%) for another resolution [1] - 224,830,564 votes in favor (99.7412%) for yet another resolution [1] Legal Compliance - The meeting's procedures and resolutions were confirmed to be legally valid by the attending lawyers, ensuring compliance with relevant laws and regulations [7][9]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 25 日召开 2024 年年度股东大会，审议并通过《关于选举第三届董事会非独立董 事的议案》、《关于选举第三届董事会独立董事的议案》等相关议案，选举产生了 公司第三届董事会董事，完成了董事会的换届选举。公司已于同日召开第三届董 事会第一次会议，会议分别审议通过了《关于选举第三届董事会董事长的议案》、 《关于设立董事会专门委员会的议案》、《关于聘任总经理的议案》、《关于聘任副 总经理、财务总监的议案》及《关于聘任董事会秘书、证券事务代表的议案》。 现将具体情况公告如下： 一、公司第三届董事会组成情况 2025 年 6 月 25 日，公司召开 2024 年年度股东大会，选举产生公司第三届 董事会董事成员。依据《中华人民共和国公司法》、《公司章程》等相关规定，公 司于同日召开第三届董事会第一次会议，审议并通过《关于选举第三届董事会董 事长的议案》、《关于设立董事会专门委员会的议案》等相关议案，公司第三届董 事 ...

证券代码：603122 证券简称：合富中国 公告编号：2025-026 合富（中国）医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 25 日 (二)股东大会召开的地点：上海市徐汇区虹漕路 456 号光启大楼 20 楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 218 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 225,413,764 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 56.6291 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，采取现场投票和网络投票相结合的方式召开， 公司董事长李惇先生主持了本次会议。本次会议的召集、召开及表 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-027 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第三届董事会第 一次会议于 2025 年 6 月 25 日下午在上海市虹漕路 456 号光启大楼 20 楼公司董 事会议室/北京市朝阳区东三环北路 19 号嘉盛中心 1810 室以现场与视讯相结合 的方式召开，全体董事一致同意豁免本次会议提前 5 日通知的义务，会议通知于 2025 年 6 月 25 日以电子邮件或书面方式发出。本次会议由半数以上董事共同推 举李惇先生主持，应到董事 6 人，实到董事 6 人。部分高级管理人员候选人列席 了会议。会议的召开符合法律法规、《公司法》及《公司章程》的规定，会议决 议合法、有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、董事会会议审议情况 1、审议并通过了《关于选举第三届董事会董事长的议案》。 同意选举李惇为公司第三届董事会董事长。任期自董事会审议通过之日起至 本 ...